(Q43937807)

English

Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.

scientific article published on 25 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

multiple sclerosis

0 references

Josefina Nyström

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Anders Svenningsson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Anne Wickström

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

25 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

622-630

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Costs and quality of life of multiple sclerosis in Sweden.

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Measures of physical and cognitive function and work status among individuals with multiple sclerosis: a review of the literature.

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

How long can you keep working with benign multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Work ability: a new outcome measure in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1177%2F1352458512461391

21 January 2018

Identifiers

10.1177/1352458512461391

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23012254%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43937807&oldid=2104515842"